Question

A 65-year-old with new HFrEF and T2D has eGFR 35 mL/min/1.73 m² and UACR 420 mg/g. He is on ARNI, beta-blocker, and MRA. Which additional agent is guideline-directed to reduce HF hospitalization and CKD progression?

Accepted Answer

SGLT2 inhibitor

Answer

DPP-4 inhibitor

Answer

GLP-1 receptor agonist only

Answer

Thiazolidinedione

Answer

Amiodarone

Practice question

A 65-year-old with new HFrEF and T2D has eGFR 35 mL/min/1.73 m² and UACR 420 mg/g. He is on ARNI, beta-blocker, and MRA. Which additional agent is guideline-directed to reduce HF hospitalization and CKD progression?